Imprimis’ Q2-2017 Ophthalmology Revenues Increase 70 percent

August 11, 2017: By Jon Swedien

ImprimisImprimis Pharmaceuticals’ gross revenues related to ophthalmology totaled $4.7 million in Q2-2017, a 70 percent increase over Q2-2016, the San Diego-based company reported Aug. 10.

The company’s total revenues for Q2-2017 were $6.9 million, a 40 percent increase compared with Q2-2016, said Imprimis, a pharmaceutical company focused on increasing patient access and affordability to critical medicines.

Imprimis had a net income of $1.5 million, or $0.07 per share of common stock (basic). CEO Mark Baum said it was the company’s first quarter of recorded net income.

The company also noted that it achieved the milestone of its products being used in 1 million patient eyes since the launch of its ophthalmic portfolio in April 2014.

And Imprimis announced that it created a new wholly owned subsidiary, Surface Pharmaceuticals, Inc., which will focus on ocular surface disease treatments that are expected to be developed as branded drugs through the FDA’s 505(b)(2) development pathway.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022